

RAIA DROGASIL S.A.
Publicly traded company with authorized capital
CNPJ/MF 61.585.865/0001-51
NIRE 35.300.035.844

MATERIAL FACT

SUCCESSION OF THE CEO AND OF THE CHAIRMAN OF THE BOARD OF DIRECTORS

Raia Drogasil SA (“RD Saúde”), Brazil’s leading pharmaceutical retailer, informs its shareholders and the market in general of planned changes to both the Company’s management and governance as part of its succession process.

From January 1st 2025, by resolution of the Board of Directors taken on the afternoon of August 2nd, 2024, **Renato Raduan (“Raduan”)**, currently Vice-President of Pharmacy and Omnichannel Operations, Expansion, Logistics and M&A, will be elected as the Company’s new Chief Executive Officer, while **Marcello De Zagottis (“Marcello”)**, currently the Commercial and Marketing Vice-President, will become Chief Operating Officer (“COO”), a newly-created position. Raduan is 49 years old and holds a bachelor’s degree in Naval Engineering from the University of São Paulo’s Polytechnical School, an MBA from INSEAD (France) and has pursued an executive development program at Harvard (AMP). He has been vice-president of RD Saúde since 2013, having previously worked at WalMart and Accenture. Marcello, 48 years old, has a bachelor’s degree in business administration from FGV, an MBA from the University of Michigan, and has pursued an executive development program at Stanford (SEP). He joined the company in 2006, having previously worked at Borders Bookstores (USA), Arthur D. Little and Accenture. Marcello is also a member of RD Saúde’s controlling group.

In addition, **Marcílio Pousada (“Marcílio”)**, RD Saude’s current CEO, will be nominated as a member and Chairman to the Board of Directors respectively at the next Annual General Shareholders’ Meeting and Board of Directors Meeting in early 2025, while **Antônio Carlos Pipponzi (“ACP”)**, who is the current Chairman and also a member of RD Saúde's controlling group, will seek re-election to the Board, while also staying as the head of the Expansion Committee that advises the Company’s management.

These changes are part of a long-term succession planning process conducted by the Board of Directors, which aims, on an ongoing basis, at identifying, assessing and developing internal candidates for succession to the Company’s main leadership positions. For the selection of the new CEO and COO, specifically, the process was led by the Board’s People Committee under direct supervision of the Company’s controlling group. As part of the process, Raduan and Marcello were independently assessed by specialized firms, underwent continuous mentoring processes, and took part in executive development programs at leading American universities. This process was also monitored and endorsed by Marcílio, RD Saúde’s current CEO and future Chairman of the Board. Finally, the two executives will also take part in a carefully planned transition process over the next five months before assuming their new positions.

With the promotions of Raduan to CEO and of Marcello to COO, both executives with long track records of achievements at RD Saúde, with the appointment of Marcílio to lead the Board of Directors as its new Chairman, with the continued presence of ACP both on the Board and as head of the Expansion Committee, and under the long-term commitment and strategic supervision of the Pires, Galvão and Pipponzi families, this succession process will allow RD Saúde to continue to reinvent its business, to reinvigorate its management structure and to strengthen its corporate governance, all in a planned and orderly manner, with low transition risk and with the preservation of the Company’s Purpose, Values and

Culture. Finally, this planned succession process also crowns a cycle of enormous success for the Company under the executive leadership of Marcílio as its CEO and of ACP as its Chairman of the Board.

Marcílio joined RD Saúde in 2013. During his cycle as CEO of the Company, he completed the integration of Raia and Drogasil and led RD Saúde to consolidate its leadership in the Brazilian pharmaceutical retailing industry, with 3.1 thousand stores and BRL 39 billion in annualized gross revenues. He also led the Company's digital transformation, the creation of its health ecosystem, and the acquisitions both of 4Bio and Onofre. Marcílio will leave his executive position at an exceptional moment for the Company, having formed his successor and leaving an enormous legacy of value creation for shareholders. As Chairman of the Board, he will continue to support the Company's management in expanding digitalization and in the health initiative.

ACP led Raia for 36 years. Under his leadership, private equity firms Gávea and Pragma invested in the Company in 2008 and completed its IPO in 2010. Together with the Pires and Galvão families, he was one of the main architects of the merger between Raia and Drogasil. In addition to being a member of the controlling group, he has been the Chairman of RD Saúde since it was established in 2011, a period in which the Company underwent a bold digital transformation, revamped its execution and strengthened both its corporate governance and its investments in sustainability. He has also personally led the largest organic growth in the history of Brazilian retailing, having opened more than 2,000 pharmacies in just 13 years while achieving benchmarks in revenues per store, in store profitability, and in internal rate of returns (IRR) that are unmatched in the sector. He was also Chairman of IDV (Institute for Retail Development) from 2017 to 2019 and has remained a member of its Board of Directors ever since.

The Board of Directors congratulates, thanks, and wishes success to Raduan, Marcello, Marcílio and ACP in their new leadership cycles at RD Saúde.

São Paulo, August 6, 2024.

RAIA DROGASIL S.A.

Flavio de Moraes Correia
Investor Relations Officer

❖ **We invite our shareholders and the market in general to a teleconference on RD Saúde's succession process, featuring our Chairman of the Board, Antônio Carlos Pipponzi, and our CEO, Marcílio Pousada.**

Date and time: August 7, 2024 at 11:30 a.m. (Brasília time, UTC/GMT -3),
with simultaneous translation into English.

Access the teleconference here:
<https://www.resultadosrdsaude.com.br/>